These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 30938150)

  • 1. Ultrasensitive Fluorescence Detection of Alzheimer's Disease Based on Polyvalent Directed Peptide Polymer Coupled to a Nanoporous ZnO Nanoplatform.
    Lee SC; Park HH; Kim SH; Koh SH; Han SH; Yoon MY
    Anal Chem; 2019 May; 91(9):5573-5581. PubMed ID: 30938150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reappraisal of Aβ40 and Aβ42 Peptides Measurements in Cerebrospinal Fluid of Patients with Alzheimer's Disease.
    Fiorini M; Bongianni M; Benedetti MD; Monaco S; Zanusso G
    J Alzheimers Dis; 2018; 66(1):219-227. PubMed ID: 30282368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Low-Molecular-Weight Aβ42 Detection System Using a Enzyme-Linked Peptide Assay.
    Kim SH; Lee EH; Kim HJ; Kim AR; Kim YE; Lee JH; Yoon MY; Koh SH
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.
    Hansson O; Lehmann S; Otto M; Zetterberg H; Lewczuk P
    Alzheimers Res Ther; 2019 Apr; 11(1):34. PubMed ID: 31010420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasensitive diagnosis for an anthrax-protective antigen based on a polyvalent directed peptide polymer coupled to zinc oxide nanorods.
    Park HY; Gedi V; Kim J; Park HC; Han SH; Yoon MY
    Adv Mater; 2011 Dec; 23(45):5425-9. PubMed ID: 21997757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease.
    Andreasen N; Blennow K
    Peptides; 2002 Jul; 23(7):1205-14. PubMed ID: 12128078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays.
    Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J
    J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease.
    Cohen AD; Landau SM; Snitz BE; Klunk WE; Blennow K; Zetterberg H
    Mol Cell Neurosci; 2019 Jun; 97():3-17. PubMed ID: 30537535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease.
    Biscetti L; Salvadori N; Farotti L; Cataldi S; Eusebi P; Paciotti S; Parnetti L
    Clin Chim Acta; 2019 Jul; 494():71-73. PubMed ID: 30844364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease.
    Gao CM; Yam AY; Wang X; Magdangal E; Salisbury C; Peretz D; Zuckermann RN; Connolly MD; Hansson O; Minthon L; Zetterberg H; Blennow K; Fedynyshyn JP; Allauzen S
    PLoS One; 2010 Dec; 5(12):e15725. PubMed ID: 21209907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
    J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study.
    Manca C; Rivasseau Jonveaux T; Roch V; Marie PY; Karcher G; Lamiral Z; Malaplate C; Verger A
    J Neurol; 2019 Jul; 266(7):1685-1692. PubMed ID: 30963253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
    Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls.
    Pannee J; Portelius E; Oppermann M; Atkins A; Hornshaw M; Zegers I; Höjrup P; Minthon L; Hansson O; Zetterberg H; Blennow K; Gobom J
    J Alzheimers Dis; 2013; 33(4):1021-32. PubMed ID: 23076076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease.
    Teunissen CE; Chiu MJ; Yang CC; Yang SY; Scheltens P; Zetterberg H; Blennow K
    J Alzheimers Dis; 2018; 62(4):1857-1863. PubMed ID: 29614646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease.
    Pottiez G; Yang L; Stewart T; Song N; Aro P; Galasko DR; Quinn JF; Peskind ER; Shi M; Zhang J
    J Proteome Res; 2017 Mar; 16(3):1228-1238. PubMed ID: 28112948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
    J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.